Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) Cash Flow for Dividends: ¥-47 Mil (TTM As of Jun. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Jiangsu Deyuan Pharmaceutical Co Ltd BJSE:920735

97 GF Score

Price ¥26.66

GF Value ¥29.61

Valuation Modestly Undervalued

2 Warning Signs

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

What is Jiangsu Deyuan Pharmaceutical Co Cash Flow for Dividends?

Jiangsu Deyuan Pharmaceutical Co BJSE:920735 97 Cash Flow for Dividends is ¥-47 Mil as of Jun. 2026. GuruFocus rates BJSE:920735 with a GF Score™ of 97/100 and a GF Value™ of ¥29.61 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Jiangsu Deyuan Pharmaceutical Co's cash flow for dividends for the three months ended in Jun. 2026 was ¥-47 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Jun. 2026 was ¥-47 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Jiangsu Deyuan Pharmaceutical Co's quarterly payment of dividends increased from Dec. 2025 (¥-0 Mil) to Mar. 2026 (¥-0 Mil) and increased from Mar. 2026 (¥-0 Mil) to Jun. 2026 (¥-47 Mil).

Jiangsu Deyuan Pharmaceutical Co's annual payment of dividends increased from Dec. 2023 (¥-24 Mil) to Dec. 2024 (¥-29 Mil) and increased from Dec. 2024 (¥-29 Mil) to Dec. 2025 (¥-36 Mil).

Try GuruFocus Premium free for 7 days

Unlock GF Score, GF Value, 30-Y financials, and pro screeners.

Get Started →

Jiangsu Deyuan Pharmaceutical Co Cash Flow for Dividends Related Terms

Jiangsu Deyuan Pharmaceutical Co Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Jiangsu Deyuan Pharmaceutical Co's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Deyuan Pharmaceutical Co Cash Flow for Dividends Chart

Jiangsu Deyuan Pharmaceutical Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Cash Flow for Dividends

Get a 7-Day Free Trial

-18.17

-20.71

-23.58

-28.93

-36.38

Jiangsu Deyuan Pharmaceutical Co Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26	Jun26
Cash Flow for Dividends	Get a 7-Day Free Trial															-36.16	-0.02	-0.01	-0.05	-46.99

97GF Score

Jiangsu Deyuan Pharmaceutical Co Ltd BJSE:920735

Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

Jiangsu Deyuan Pharmaceutical Co Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-47 Mil.

Frequently Asked Questions Learn more about Cash Flow for Dividends →

What does a Cash Flow for Dividends of ¥-47 Mil mean?

Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) has a Cash Flow for Dividends of ¥-47 Mil as of Jun. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Jiangsu Deyuan Pharmaceutical Co and its competitors.

Is Jiangsu Deyuan Pharmaceutical Co's Cash Flow for Dividends too high?

Jiangsu Deyuan Pharmaceutical Co's current Cash Flow for Dividends is ¥-47 Mil. Overall, Jiangsu Deyuan Pharmaceutical Co has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Jiangsu Deyuan Pharmaceutical Co's Cash Flow for Dividends compare to ZTS?

Jiangsu Deyuan Pharmaceutical Co's Cash Flow for Dividends of ¥-47 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash Flow for Dividends for a Drug Manufacturers company?

A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash Flow for Dividends mean?

A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Jiangsu Deyuan Pharmaceutical Co and its competitors. Jiangsu Deyuan Pharmaceutical Co's current Cash Flow for Dividends is ¥-47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Jiangsu Deyuan Pharmaceutical Co stock overvalued right now?

Based on GuruFocus' analysis, Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥29.61, compared to a current price of ¥26.66 — trading 10% below its estimated fair value. The current Cash Flow for Dividends is ¥-47 Mil. Jiangsu Deyuan Pharmaceutical Co's overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash Flow for Dividends calculated?

Cash Flow for Dividends is calculated from a company's financial statements. For Jiangsu Deyuan Pharmaceutical Co (BJSE:920735), the current Cash Flow for Dividends is ¥-47 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Deyuan Pharmaceutical Co (BJSE:920735) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Deyuan Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥26.66 is trading 10% below its estimated GF Value™ of ¥29.61. GuruFocus considers Jiangsu Deyuan Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for BJSE:920735:

Cash Flow for Dividends: ¥-47 Mil
GF Value™: ¥29.61 vs. price of ¥26.66 (10% below fair value)
GF Score™: 97/100 with 2 warning signs

No single metric tells the full story. See the BJSE:920735 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →